Ovid Therapeutics Stock Earnings Per Share
| OVID Stock | USD 1.09 0.01 0.91% |
Ovid Therapeutics fundamentals help investors to digest information that contributes to Ovid Therapeutics' financial success or failures. It also enables traders to predict the movement of Ovid Stock. The fundamental analysis module provides a way to measure Ovid Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ovid Therapeutics stock.
Ovid | Earnings Per Share |
Ovid Therapeutics Company Earnings Per Share Analysis
Ovid Therapeutics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Ovid Therapeutics Earnings Per Share | (0.46) X |
Most of Ovid Therapeutics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ovid Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ovid Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Ovid Therapeutics is extremely important. It helps to project a fair market value of Ovid Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Ovid Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ovid Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ovid Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
Ovid Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, Ovid Therapeutics has an Earnings Per Share of -0.46 times. This is 105.5% lower than that of the Biotechnology sector and 90.4% lower than that of the Health Care industry. The earnings per share for all United States stocks is 114.74% higher than that of the company.
Ovid Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ovid Therapeutics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ovid Therapeutics could also be used in its relative valuation, which is a method of valuing Ovid Therapeutics by comparing valuation metrics of similar companies.Ovid Therapeutics is currently under evaluation in earnings per share category among its peers.
Ovid Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ovid Therapeutics from analyzing Ovid Therapeutics' financial statements. These drivers represent accounts that assess Ovid Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ovid Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 162.8M | 135.0M | 216.6M | 131.0M | 227.3M | 132.9M | |
| Enterprise Value | 120.9M | 63.0M | 28.8M | 18.5M | 216.2M | 108.5M |
Ovid Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (76.45) % | ||||
| Current Valuation | 30.47 M | ||||
| Shares Outstanding | 71.01 M | ||||
| Shares Owned By Insiders | 15.89 % | ||||
| Shares Owned By Institutions | 56.45 % | ||||
| Number Of Shares Shorted | 679.89 K | ||||
| Price To Earning | 1.11 X | ||||
| Price To Book | 1.02 X | ||||
| Price To Sales | 123.65 X | ||||
| Revenue | 391.69 K | ||||
| Gross Profit | 1.5 M | ||||
| EBITDA | (58.71 M) | ||||
| Net Income | (52.34 M) | ||||
| Cash And Equivalents | 152.37 M | ||||
| Cash Per Share | 2.16 X | ||||
| Total Debt | 16 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 16.94 X | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | (45.78 M) | ||||
| Short Ratio | 7.01 X | ||||
| Earnings Per Share | (0.46) X | ||||
| Target Price | 3.26 | ||||
| Number Of Employees | 25 | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 78.11 M | ||||
| Total Asset | 144.03 M | ||||
| Retained Earnings | (277.87 M) | ||||
| Working Capital | 98.12 M | ||||
| Current Asset | 74.21 M | ||||
| Current Liabilities | 5.13 M | ||||
| Net Asset | 144.03 M |
About Ovid Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ovid Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ovid Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ovid Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:Check out Ovid Therapeutics Piotroski F Score and Ovid Therapeutics Altman Z Score analysis. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.009 | Quarterly Revenue Growth 0.587 | Return On Assets (0.36) | Return On Equity (0.37) |
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.